Under construction – not a live service

Skip to content

Frontlight Research

Search a disease

Frequently searched

↑ ↓ to move · Enter to open · Esc to closeSynonyms and typos are matched

Home/Doctors/Kidney cancer

For doctors

Kidney cancer: trials for referral

526 open trials in the registries we read. Each row links to its registry record.

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Kidney cancer·What we know·Glossary·Tumour board sheet

Where the open trials are

Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.

Your city

Only trials with a pre-treatment window

400 trials shown · Showing the 400 most recently updated of 526 open trials.

Phase 20 sites
Not yet recruiting
NCT07922915
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 1/260 sites
RecruitingSouth Korea, Singapore, Taiwan, United States
NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Pre-treatment window Registry sentence: “For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC.”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 20 sites
Not yet recruiting
NCT07922928
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Sun Yat-sen University
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 21 site
RecruitingUnited States
NCT05155033
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 21 site
RecruitingChina
NCT07087158
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 2582 sites
RecruitingPuerto Rico, United States
NCT03866382
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly \> or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly \> or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed.”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 1/227 sites
RecruitingSouth Korea, United States
NCT03972657
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 116 sites
RecruitingUnited States
NCT07300241
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 22 sites
RecruitingUnited States
NCT05830058
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 111 sites
RecruitingBelgium, Spain, United States
NCT05856981
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 1/21 site
RecruitingUnited States
NCT05663710
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 1/22 sites
RecruitingUnited States
NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
VM Discovery, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 3429 sites
RecruitingUnited States
NCT06661720
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology
Pre-treatment window Registry sentence: “No prior systemic treatment for RCC”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 121 sites
RecruitingAustralia, Spain, South Korea, United States
NCT05536141
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Arcus Biosciences, Inc.
Pre-treatment window Registry sentence: “For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib.”
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 3226 sites
RecruitingArgentina, Australia, Canada, Czechia, Germany, Spain
NCT07011719
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Pre-treatment window Registry sentence: “Ongoing clinically significant toxicities related to any prior anticancer treatment, or toxicities Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) regardless of relatedness to prior anticancer therapies.”
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
No phase0 sites
Not yet recruiting
NCT07911527
The Edison™ System for Treatment of Renal Tumors Using Histotripsy (Histo-Renal Trial)
Chinese University of Hong Kong
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 21 site
RecruitingChina
NCT07909265
Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 25 sites
RecruitingAustralia
NCT07072728
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 1/21 site
RecruitingUnited States
NCT02830724
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 30 sites
Not yet recruiting
NCT07904156
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 3109 sites
RecruitingArgentina, Australia, Brazil, Canada, Chile, Czechia
NCT07489495
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Merck Sharp & Dohme LLC
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 21 site
RecruitingUnited States
NCT06601296
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
University of Texas Southwestern Medical Center
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
No phase1 site
By invitation onlyUnited States
NCT00102544
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
National Institutes of Health Clinical Center (CC)
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 112 sites
RecruitingAustralia, United Kingdom, United States
NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 10 sites
Not yet recruiting
NCT07252661
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 34 sites
By invitation onlyUnited States
NCT07620574
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 232 sites
RecruitingUnited States
NCT04616560
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
National Cancer Institute (NCI)
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
Phase 213 sites
RecruitingUnited States
NCT04981509
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “No prior treatment with PD-1 or PD-L1 inhibitors in the metastatic/advanced setting.”
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
No phase1 site
RecruitingItaly
NCT07285538
Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer
IRCCS San Raffaele
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site
No phase0 sites
Not yet recruiting
NCT07689812
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Natera, Inc.
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.gov
Compare criteriaReferral pack Letter to the site

893 sites Pre-treatment window

The same sites as a list

Who treats this

Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.

Aarhus University Hospital
Aarhus, Denmark
7 trials · 22 publications · ROR
Affiliated Hospital of Qingdao University
Qingdao, China
3 trials · 23 publications · ROR
Agostino Gemelli University Polyclinic
Rome, Italy
17 trials · 44 publications · ROR
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Canada
6 trials · 29 publications · ROR
Asan Medical Center
Seoul, South Korea
33 trials · 38 publications · ROR
Assistance Publique – Hôpitaux de Paris
Paris, France
19 trials · 24 publications · ROR
Azienda Ospedaliero Universitaria Maggiore della Carita
Novara, Italy
4 trials · 25 publications · ROR
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
6 trials · 31 publications · ROR
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari
Bari, Italy
6 trials · 28 publications · ROR
Beth Israel Deaconess Medical Center
Boston, United States
23 trials · 57 publications · ROR
Brigham and Women's Hospital
Boston, United States
14 trials · 95 publications · ROR
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, China
8 trials · 22 publications · ROR
Candiolo Cancer Institute
Candiolo, Italy
2 trials · 23 publications · ROR
Case Western Reserve University
Cleveland, United States
8 trials · 28 publications · ROR
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
32 trials · 22 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
1 trial · 69 publications · ROR
Chinese PLA General Hospital
Beijing, China
1 trial · 49 publications · ROR
City Of Hope National Medical Center
Duarte, United States
18 trials · 86 publications · ROR
Cleveland Clinic
Cleveland, United States
21 trials · 81 publications · ROR
Dana-Farber Cancer Institute
Boston, United States
82 trials · 187 publications · ROR
Duke Medical Center
Durham, United States
37 trials · 24 publications · ROR
Duke University
Durham, United States
4 trials · 32 publications · ROR
Emory University
Atlanta, United States
6 trials · 65 publications · ROR
European Institute of Oncology
Milan, Italy
3 trials · 29 publications · ROR
First Affiliated Hospital of Anhui Medical University
Hefei, China
2 trials · 24 publications · ROR
First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
5 trials · 25 publications · ROR
First Affiliated Hospital Zhejiang University
Hangzhou, China
3 trials · 27 publications · ROR
First Hospital of Shanxi Medical University
Taiyuan, China
1 trial · 21 publications · ROR
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
35 trials · 38 publications · ROR
Fox Chase Cancer Center
Philadelphia, United States
21 trials · 27 publications · ROR

What changed in the last 7 days

RSS feed (30 days)Calendar reminder

Registry facts, one per line, newest first.

6 Nov 2026
New in the registry
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
NCT07922915 · Phase 2
Source: ClinicalTrials.gov
6 Nov 2026
New in the registry
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
NCT07922928 · Phase 2
Source: ClinicalTrials.gov
5 Nov 2026
Phase changed: Phase 1/2 → Phase 1
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
NCT05795595 · Phase 1 · United States
Source: ClinicalTrials.gov
16 Jan 2026
Status changed: Recruiting → Not yet recruiting
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
NCT07346404 · Phase 2 · France
Source: ClinicalTrials.gov
23 Oct 2026
Opened for recruitment
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351 · Phase 1/2 · Argentina, Australia, Canada, Switzerland, Chile, China
Source: ClinicalTrials.gov
28 Apr 2026
Opened for recruitment
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680 · Phase 1/2 · Germany, Spain, France, Italy, United States
Source: ClinicalTrials.gov
8 Apr 2026
Status changed: Completed → Running, not recruiting
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782 · Phase 2 · Argentina, Australia, Chile, France, Japan, New Zealand
Source: ClinicalTrials.gov
5 Jun 2026
Phase changed: Phase 2 → Phase 1/2
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
NCT05765084 · Phase 1/2 · Belgium
Source: ClinicalTrials.gov
29 Jul 2026
Closed for recruitment
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673 · Phase 3 · Argentina, Australia, Bulgaria, Brazil, Chile, Czechia
Source: ClinicalTrials.gov
8 May 2026
Opened for recruitment
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
NCT05363280 · Phase 2 · Spain, Italy, United States
Source: ClinicalTrials.gov
18 Mar 2026
Phase changed: Phase 2 → Phase 1/2
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
NCT05384821 · Phase 1/2 · France
Source: ClinicalTrials.gov
29 Oct 2025
Closed for recruitment
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882 · Phase 1 · Australia, Germany, Spain, France, Israel, Japan
Source: ClinicalTrials.gov
22 Sept 2026
Status changed: Completed → Running, not recruiting
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
NCT04810078 · Phase 3 · Argentina, Brazil, Chile, Czechia, Spain, Finland
Source: ClinicalTrials.gov
7 Sept 2020
Opened for recruitment
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532 · Phase 3 · Spain, France, United Kingdom
Source: ClinicalTrials.gov
27 Jun 2025
Phase changed: Phase 1/2 → Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224 · Phase 2 · Australia, Canada, Spain, France, United Kingdom, Hungary
Source: ClinicalTrials.gov
29 Apr 2025
Phase changed: Phase 2 → Phase 1/2
Autologous Dendritic Cell Vaccination in Mesothelioma
NCT02649829 · Phase 1/2 · Belgium
Source: ClinicalTrials.gov
6 Aug 2025
Opened for recruitment
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
NCT07346404 · Phase 2 · France
Source: ClinicalTrials.gov
31 Jul 2026
New in the registry
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479 · Phase 1/2 · Australia, Canada, Chile, Colombia, Spain, France
Source: ClinicalTrials.gov
28 Oct 2026
Opened for recruitment
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673 · Phase 3 · Argentina, Australia, Bulgaria, Brazil, Chile, Czechia
Source: ClinicalTrials.gov
13 Feb 2026
Closed for recruitment
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532 · Phase 3 · Spain, France, United Kingdom
Source: ClinicalTrials.gov

Show more

30 Sept 2026
Status changed: Recruiting → Not yet recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351 · Phase 1/2 · Argentina, Australia, Canada, Switzerland, Chile, China
Source: ClinicalTrials.gov
19 Jun 2026
Status changed: Recruiting → Not yet recruiting
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680 · Phase 1/2 · Germany, Spain, France, Italy, United States
Source: ClinicalTrials.gov
11 Aug 2026
Opened for recruitment
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882 · Phase 1 · Australia, Germany, Spain, France, Israel, Japan
Source: ClinicalTrials.gov
4 Sept 2026
Closed for recruitment
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
NCT05363280 · Phase 2 · Spain, Italy, United States
Source: ClinicalTrials.gov

New reviews, guidelines and randomised trials in PubMed

4 Nov 2026
Meta-analysis
Prognostic value of lymphocyte to monocyte ratio for metastatic renal cell carcinoma: a systematic review and meta-analysis.
BMC cancer · PubMed

Results card

Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.

Phase 2Ended 5 Oct 2026
Completed199 participants
NCT05805501
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Registry record
Phase 2Ended 1 Oct 2026
Stopped early22 participants
NCT06005818
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
Reason given: Loss of funding
Registry record
Phase 2Ended 30 Sept 2026
Stopped early73 participants
NCT05879822
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Reason given: This was a strategic business decision. There were no safety concerns contributing to this decision.
Registry record
Phase 2Ended 30 Sept 2026
Completed113 participants
2023-505816-39-00
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Registry record
Phase 2Ended 22 Sept 2026
Completed84 participants
NCT03581773
Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy
Registry record
No phaseEnded 1 Sept 2026
Completed1334 participants
NCT05225428
Video Education With Result Dependent dIsclosure
Registry record
Phase 2/3Ended 28 Aug 2026
Completed265 participants
NCT05522231
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
Registry record
Phase 1Ended 26 Aug 2026
Completed215 participants
NCT04084067
Indocyanine Green (ICG) Guided Tumor Resection
Registry record
No phaseEnded 26 Aug 2026
Completed7 participants
NCT05899361
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Registry record
Phase 1/2Ended 25 Aug 2026
Completed15 participants
NCT05363631
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
Registry record
Phase 2Ended 25 Aug 2026
Completed154 participants
NCT04489771
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Registry record
Phase 1/2Ended 10 Aug 2026
Completed393 participants
NCT04626479
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Registry record
Phase 2Ended 4 Aug 2026
Completed30 participants
NCT03587662
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Registry record
Phase 1Ended 31 Jul 2026
Completed18 participants
NCT05858736
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Registry record
No phaseEnded 26 Jul 2026
Completed120 participants
NCT02399124
Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma
Registry record
Phase 1/2Ended 23 Jul 2026
Completed263 participants
NCT04626518
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Registry record
Phase 1Ended 16 Jul 2026
Completed138 participants
NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Registry record
No phaseEnded Jun 2026
Withdrawn before start0 participants
NCT06603155
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
Reason given: Changing priorities of portfolio
Registry record
No phaseEnded 30 Jun 2026
Completed228 participants
NCT07827482
Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma
Registry record
Phase 2Ended 30 Jun 2026
Completed66 participants
NCT04090710
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Registry record

Show more

No phaseEnded 30 Jun 2026
Completed60 participants
NCT07778628
WT1 in Colorectal Adenocarcinoma
Registry record
Phase 2Ended 29 Jun 2026
Completed138 participants
NCT02992912
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
Registry record
Phase 1/2Ended 2 Jun 2026
Completed98 participants
NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Registry record
No phaseEnded 19 May 2026
Completed3 participants
NCT06195150
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
Registry record
No phaseEnded 6 May 2026
Completed48 participants
NCT07024680
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
Registry record
Phase 1Ended 22 Apr 2026
Completed156 participants
NCT05479812
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Registry record
No phaseEnded 13 Apr 2026
Completed120 participants
NCT06955910
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Registry record
Phase 1Ended 11 Apr 2026
Completed29 participants
NCT04846920
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
Registry record
No phaseEnded 10 Apr 2026
Stopped early106 participants
NCT06456411
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
Reason given: PI left
Registry record
Phase 1/2Ended 9 Apr 2026
Completed128 participants
2024-516711-24-00
A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS
Registry record
Phase 3Ended 1 Apr 2026
Completed701 participants
NCT03141177
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER. · The oncologist, 2026
- Summary of Research: Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. · Advances in therapy, 2026
- Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. · Oncology and therapy, 2026
Registry record
No phaseEnded 1 Apr 2026
Completed28 participants
NCT03630536
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
Registry record
Phase 3Ended 31 Mar 2026
Completed808 participants
NCT00352534
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Registry record
Phase 3Ended 31 Mar 2026
Completed249 participants
NCT00945009
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Registry record
Phase 3Ended 31 Mar 2026
Completed395 participants
NCT00379340
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Registry record
No phaseEnded 31 Mar 2026
Completed8000 participants
NCT00898365
Study of Kidney Tumors in Younger Patients
- Feasibility of Real-Time Central Risk Assignment for Children's Oncology Group Pediatric Renal Tumor Trials. · Pediatric blood & cancer, 2026
Registry record
No phaseEnded 27 Mar 2026
Completed370 participants
NCT06056505
Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy
Registry record
No phaseEnded 26 Mar 2026
Completed1229 participants
NCT06822842
Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models
Registry record
No phaseEnded 23 Mar 2026
Completed72 participants
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Registry record
Phase 2Ended 18 Mar 2026
Completed30 participants
NCT04644432
A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer
Registry record
Early Phase 1Ended 17 Mar 2026
Withdrawn before start0 participants
NCT06708936
KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study
Reason given: Due to a strategic adjustment, the company has decided to terminate the project.
Registry record
Phase 2Ended 11 Mar 2026
Stopped early15 participants
NCT04904302
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
Reason given: Withdrawal of funding from the supporter (Mirati Therapeutics)
Registry record
Phase 1Ended 6 Mar 2026
Stopped early1 participant
NCT05397093
ITIL-306 in Advanced Solid Tumors
Reason given: The study was terminated early due to discontinuation of development of the investigational program
Registry record
Early Phase 1Ended 5 Mar 2026
Completed17 participants
NCT04028245
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
Registry record
Phase 1Ended 4 Mar 2026
Completed26 participants
NCT04495257
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Registry record
Phase 2Ended 12 Feb 2026
Completed127 participants
NCT03945773
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Registry record
Phase 1Ended 10 Feb 2026
Stopped early21 participants
NCT05861947
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Reason given: Patient recruitment problems
Registry record
No phaseEnded 9 Feb 2026
Completed190 participants
NCT04146064
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Registry record
Phase 3Ended 4 Feb 2026
Completed994 participants
NCT03142334
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Registry record
Phase 2Ended 1 Feb 2026
Stopped early29 participants
NCT06760702
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers
Reason given: Patient recruitment problems.
Registry record
Phase 1Ended 26 Jan 2026
Stopped early30 participants
NCT05462873
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Reason given: Business decision and not related to safety concerns
Registry record
Phase 1/2Ended 23 Jan 2026
Completed12 participants
NCT06716853
A clinical gene therapy study with hematopoietic stem cells for the treatment, with single dose of Temferon, of patients suffering from metastatic renal cell carcinoma
Registry record
No phaseEnded 23 Jan 2026
Completed64 participants
NCT03707574
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
Registry record
Phase 3Ended 20 Jan 2026
Completed343 participants
NCT04987203
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Registry record
Phase 2Ended 10 Jan 2026
Stopped early17 participants
NCT06114940
Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)
Reason given: Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for subjects' endpoints before and after the change.
Registry record
Phase 2Ended 31 Dec 2025
Completed28 participants
NCT05256472
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Registry record
Phase 2Ended 31 Dec 2025
Completed20 participants
NCT05877820
A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
- Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis. · Nature communications, 2026
Registry record
Phase 2Ended 31 Dec 2025
Completed39 participants
NCT06138496
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Registry record
No phaseEnded 31 Dec 2025
Stopped early137 participants
NCT04681690
German National Registry for NSS
Reason given: Lack of financial support
Registry record
No phaseEnded 31 Dec 2025
Completed32949 participants
NCT07821775
Robotic vs Laparoscopic and Open Surgery for Abdominopelvic Cancers
Registry record

Not medical advice. fetched 10 Nov 2026

Report an error

Frontlight Research

Medical research worldwide, searchable by disease and dated at every step.

Diseases

Acute myeloid leukemia
Alzheimer disease
Childhood cancers
Colorectal cancer
Gastric and esophageal cancer
Glioblastoma
Liver and biliary tract cancer
Long COVID and ME/CFS
Lung cancer
Metastatic breast cancer
Multiple myeloma
Multiple sclerosis
Ovarian cancer
Pancreatic cancer
Parkinson disease

All diseases A–Z

For you

Patients
Doctors
Researchers

About

About Frontlight
Data sources
How summaries are made
Editorial checks & sources
Contact

Not medical advice. Texts marked “Machine summary” are generated automatically from registry and publication data and can be wrong. Sources: ClinicalTrials.gov, EU CTIS, PubMed, OpenAlex; WHO ICTRP coming soon.

Terms
Privacy
Cookies
Imprint

© 2026 Frontlight Research